Oct 1, 2018
Our guest on the show is Dr. Lindsay McNair, Chief Medical
Officer for the WIRB-Copernicus Group, a central Institutional
Review Board (IRB) overseeing more than 200,000 clinical research
protocols and more than 2,700 institutions and 700 local
Institutional Biosafety Committees.
In her current role, Dr. McNair develops strategic partnerships
with pharma/biotech companies for comprehensive ethical and
clinical services. She oversees a consulting group which provides
consultation on human research protection, ethical trial design,
protocol development, development of ethical clinical research
policy and practices and much more.
Dr. McNair has more than 15 years of experience in clinical
research and drug development strategy. She has designed and
provided medical monitoring for Phase 1-4 clinical studies in a
variety of therapeutic areas, including multiple oncology
indications, hepatitis C, multiple inflammation indications
(psoriasis, multiple sclerosis) and other areas.
Dr. McNair is also an adjunct Assistant Professor at Boston
University and teaches in the School of Public Health and in the
Master’s of Clinical Investigation graduate programs, on the design
and conduct of clinical research studies.
She speaks frequently on the ethical conduct of clinical research
studies as part of pharmaceutical drug development and improving
interactions between ethics committees/ research review boards and
the pharmaceutical industry.
Dr. McNair graduated from the University Of Connecticut School Of
Medicine and trained in general surgery at Boston University
Medical Center. She has a Master’s in Public Health
(Biostatistics/Epidemiology and Health Policy), and a Master’s of
Science in Bioethics (research ethics).
Please join me in welcoming Dr. Lindsay McNaire on the Clinical Trial Podcast.
This episode is brought to you by CBI Events.
The team at CBI has put together a Digital Therapeutics event in New York City on December 3-4, 2018. Topics range from strategies for new digital health projects to perspectives from the venture capital community on investment requirements for digital therapeutics.
Whether you’re a pioneer in this space or want to know just the right amount of information to get started, this event is going to value packed for you.
Some benefits from your participation in this event include:
- Learning strategies on how to ensure data integrity
- Understanding regulatory approaches to digital therapeutics and how to seamless approval in all regions
- Finding out about payer approval requirements and uncovering changing business models
- Collaborating with others on standard definitions and approaches to what constitutes a digital therapeutic
- And much, much, more.
If you want to learn and network with others in the Digital
Therapeutics space, you should attend the 2018 event in New York
City on December 3-4, 2018.
As a listener to this podcast, I’ve got an exclusive $500 discount
to this event. When I mean exclusive, it really is exclusive.
So head over to http://www.cbinet.com/digitaltherapeutics
and use the code CTP500 at check-out to get your $500 discount.
Register today to get your exclusive $500 off your event ticket using the code CTP500. This offer is only available to the Clinical Trial Podcast listeners.